Radnor, PA, United States of America

Jaakko Lappalainen


Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Radnor, PA (US) (2019 - 2021)
  • Wilmington, DE (US) (2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Jaakko Lappalainen: Innovator in Neurosteroid Treatments

Introduction

Jaakko Lappalainen, an accomplished inventor based in Radnor, Pennsylvania, has made significant strides in the field of pharmacology. With a focus on neurosteroid formulations, Lappalainen holds four patents that underscore his contributions to treating various depressive disorders, including postpartum depression.

Latest Patents

Lappalainen's notable patents include a groundbreaking innovation involving the use of ganaxolone for the prophylaxis and treatment of postpartum depression. This patent describes a method wherein a dose of ganaxolone is administered to women suffering from or at risk of developing postpartum depression, aimed at alleviating at least one symptom of this condition. Additionally, he has patented methods for treating depressive disorders and delirium tremens, which involve administering an effective amount of injectable formulations of neurosteroids, including ganaxolone. His formulations include innovative combinations such as ganaxolone with sulfobutyl ether β-cyclodextrin and other neurosteroids, surface stabilizers, and surfactants.

Career Highlights

Lappalainen's work at Marinus Pharmaceuticals has been pivotal in advancing treatments for mental health disorders. His inventive approaches have the potential to transform therapeutic practices and improve patient outcomes. The focus on injectable neurosteroid formulations is particularly significant, as it opens new avenues for treatment resistant cases where traditional methods may fall short.

Collaborations

At Marinus Pharmaceuticals, Lappalainen collaborates with esteemed colleagues, including Christopher Cashman and David Czekai. Their combined expertise fosters a productive environment that drives innovative research and development in neuropharmacology, enabling the creation of effective treatments for complex psychiatric conditions.

Conclusion

Jaakko Lappalainen stands out as a leading inventor in the domain of neurosteroids for mental health treatments. His contributions, marked by four patents, highlight his commitment to addressing critical health issues such as postpartum depression and depressive disorders. Through his innovative work and collaborations, Lappalainen continues to pave the way for advancements in the field of pharmacological therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…